• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ionis announces the appointment of Michael Yang to Board of Directors

    12/14/23 4:05:00 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IONS alert in real time by email

    CARLSBAD, Calif., Dec. 14, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced the appointment of Michael Yang, an experienced biopharmaceutical executive, to the Ionis Board of Directors. Mr. Yang's appointment expands the total number of Ionis Board members to 10.

    (PRNewsfoto/Ionis Pharmaceuticals, Inc.)

    Mr. Yang has more than 20 years of broad senior level leadership experience in biotech, pharmaceutical and medical device companies, where he launched new platforms, expanded global revenues and diversified product lines. He most recently served as President, Chief Executive Officer and Board member of ViaCyte, which was acquired by Vertex in 2022. Prior to ViaCyte, Mr. Yang was Executive Vice President and Chief Commercial Officer at Acadia Pharmaceuticals from 2017 to 2021. During his tenure, Acadia transformed the standard of care for patients with Parkinson's disease psychosis. Prior to Acadia, Mr. Yang was President of Janssen Biotech Inc., where he was responsible for building Janssen's U.S. immunology business, generating more than $8 billion in annual revenues.

    "We are thrilled for Michael to join the Board as he adds deep biopharmaceutical leadership experience, particularly important as Ionis is poised to enter its next phase of growth," said Joseph Loscalzo, M.D., Ph.D., chairman of the Ionis Board of Directors. "Michael's commercial experience launching innovative medicines for patients in need will be highly complementary to the strong science and business expertise on the Board. We welcome his guidance and insights."

    "I have known Michael for many years and have always appreciated his wide-ranging experience in both rare and common diseases as well as the strong patient focus he brings to our industry," said Brett P. Monia, Ph.D., Ionis' chief executive officer. "We are thrilled to have him as part of the Board and the Ionis team looks forward to working with him." 

    About Ionis Pharmaceuticals, Inc.

    For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care. Ionis currently has four marketed medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision to become the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.

    To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.

    Ionis' Forward-looking Statements

    This press release includes forward-looking statements regarding Ionis' business, and the therapeutic and commercial potential of Ionis' technologies, and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions, or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2022, and most recent Form 10-Q, which are on file with the SEC. Copies of these and other documents are available at www.ionispharma.com.

    Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-announces-the-appointment-of-michael-yang-to-board-of-directors-302014842.html

    SOURCE Ionis Pharmaceuticals, Inc.

    Get the next $IONS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IONS

    DatePrice TargetRatingAnalyst
    9/26/2025$65.00Sell → Neutral
    Goldman
    9/3/2025$70.00Market Perform → Outperform
    BMO Capital Markets
    7/31/2025$62.00Equal-Weight → Overweight
    Morgan Stanley
    7/1/2025$57.00Equal Weight → Overweight
    Barclays
    4/7/2025$45.00Buy
    H.C. Wainwright
    3/31/2025$39.00Neutral
    Redburn Atlantic
    8/2/2024$67.00 → $60.00Outperform → Market Perform
    BMO Capital Markets
    7/24/2024$53.00 → $62.00Market Perform → Outperform
    Leerink Partners
    More analyst ratings

    $IONS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ionis Pharma upgraded by Goldman with a new price target

    Goldman upgraded Ionis Pharma from Sell to Neutral and set a new price target of $65.00

    9/26/25 8:00:14 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ionis Pharma upgraded by BMO Capital Markets with a new price target

    BMO Capital Markets upgraded Ionis Pharma from Market Perform to Outperform and set a new price target of $70.00

    9/3/25 8:16:13 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ionis Pharma upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Ionis Pharma from Equal-Weight to Overweight and set a new price target of $62.00

    7/31/25 7:07:33 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IONS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day

    – Two independent launches underway in less than nine months, with two more on track for 2026 – – Growing pipeline of wholly owned medicines in neurology and cardiometabolic disease and leading technology for next-generation medicines – – Clear path to sustained positive cash flow – – Ionis to webcast Innovation Day at 8:30 a.m. ET – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today is hosting its 2025 Innovation Day in New York City. Ionis leaders will highlight the company's recent and near-term independent launches, growing pipeline of wholly owned medicines, innovative technology and clear path to sustained positive cash flow. Additionally, a leading physician will discuss the cur

    10/7/25 7:00:00 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen

    CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Company's supplemental New Drug Application (sNDA) for the high dose regimen of nusinersen for the treatment of spinal muscular atrophy (SMA). The FDA letter requested an update to the technical information be included in the Chemistry Manufacturing and Controls (CMC) module of the sNDA. The letter did not cite any deficiencies in the clinical data of the high dose regimen. The FDA provided options for resolution, and Biogen is planning to resubmit the application promptly based upon readily availabl

    9/23/25 4:30:00 PM ET
    $BIIB
    $IONS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease

    – First and only investigational medicine to demonstrate a clinically meaningful and disease-modifying impact on this rare, often fatal neurological condition – – NDA submission planned in Q1 2026 – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced positive topline results from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, progressive and often fatal neurological condition with no approved disease-modifying treatments. Zilganersen 50 mg demonstrated statistically significant and clinically meaningful stabilization on the primary endpoint of gait speed as assessed by the 10-Meter Walk Test (10MWT) compared to control at week

    9/22/25 7:00:00 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IONS
    SEC Filings

    View All

    SEC Form 144 filed by Ionis Pharmaceuticals Inc.

    144 - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

    9/30/25 4:49:22 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

    9/22/25 7:05:51 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Ionis Pharmaceuticals Inc.

    144 - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

    9/3/25 4:37:28 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IONS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hayden Michael R bought $477,900 worth of shares (15,000 units at $31.86), increasing direct ownership by 43% to 50,219 units (SEC Form 4)

    4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

    5/2/25 4:38:26 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hayden Michael R bought $181,079 worth of shares (5,000 units at $36.22), increasing direct ownership by 17% to 35,219 units (SEC Form 4)

    4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

    12/26/24 4:57:52 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IONS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP Research Swayze Eric exercised 27,114 shares at a strike of $53.77 and sold $1,793,744 worth of shares (27,114 units at $66.16) (SEC Form 4)

    4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

    10/2/25 7:36:11 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Wender Joseph H sold $1,100,385 worth of shares (16,800 units at $65.50) (SEC Form 4)

    4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

    10/2/25 7:36:16 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Business Officer Baroldi Joseph sold $1,020,210 worth of shares (15,000 units at $68.01) and exercised 15,000 shares at a strike of $31.80 (SEC Form 4)

    4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

    10/2/25 7:35:51 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IONS
    Leadership Updates

    Live Leadership Updates

    View All

    Alltrna Announces Updates to Its Board of Directors

    Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

    7/17/24 8:00:00 AM ET
    $APRE
    $CYTK
    $EVLO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Biotechnology: Biological Products (No Diagnostic Substances)

    Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

    Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

    6/24/24 4:05:00 PM ET
    $CTNM
    $IONS
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals
    Medicinal Chemicals and Botanical Products

    Ionis announces the appointment of Michael Yang to Board of Directors

    CARLSBAD, Calif., Dec. 14, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced the appointment of Michael Yang, an experienced biopharmaceutical executive, to the Ionis Board of Directors. Mr. Yang's appointment expands the total number of Ionis Board members to 10. Mr. Yang has more than 20 years of broad senior level leadership experience in biotech, pharmaceutical and medical device companies, where he launched new platforms, expanded global revenues and diversified product lines. He most recently served as President, Chief Executive Officer and B

    12/14/23 4:05:00 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IONS
    Financials

    Live finance-specific insights

    View All

    Ionis reports second quarter 2025 financial results and highlights progress on key programs

    - TRYNGOLZATM delivers $19 million in net product sales in the second quarter 2025 - - Donidalorsen approval in hereditary angioedema (HAE) anticipated next month; Ionis' second independent launch - - Phase 3 data from the pivotal CORE and CORE2 studies in severe hypertriglyceridemia (sHTG) expected in September 2025 - - Increasing 2025 financial guidance based on strong performance and improved outlook - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company") today reported financial results and provided key updates for the second quarter ended June 30, 2025. "During the second quarter, we continued to build momentum across our business," said Brett P. Monia, Ph.D., chief execu

    7/30/25 7:00:00 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

    Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersenBased on these encouraging Phase 1 data, Biogen is engaging with regulators to advance salanersen to registrational stage studies, building on extensive experience in SMA CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced topline results from the Phase 1 study of

    6/25/25 7:30:37 AM ET
    $BIIB
    $IONS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Ionis reports first quarter 2025 financial results

    - Encouraging start to first independent launch with TRYNGOLZATM - - On track for second independent launch with donidalorsen PDUFA August 21, 2025 - - Increasing 2025 financial guidance by more than 20% - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company") today reported financial results for the first quarter ended March 31, 2025. "With an encouraging start to the TRYNGOLZA launch for familial chylomicronemia syndrome, the first of four independent launches expected over the next two years, Ionis' new chapter as a fully integrated, commercial-stage biotechnology company is well underway," said Brett P. Monia, Ph.D., chief executive officer, Ionis. "We look forward to continued m

    4/30/25 7:00:00 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IONS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc.

    SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

    11/14/24 8:34:57 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc.

    SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

    11/14/24 1:28:29 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Ionis Pharmaceuticals Inc.

    SC 13G - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

    11/8/24 10:52:38 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care